A Retrospective Toxicology Study of Polysubstance Use Patterns Associated with Xylazine
Open Access
- 14 February 2026
- journal article
- research article
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 27 (4) , 1822
Abstract
In recent years, xylazine has emerged as a cutting agent combined with illicit drugs to extend their effects. The present study aimed to discover drug use patterns associated with xylazine-positive and -negative urine toxicology drug screens and to assess whether xylazine can be used as a marker for exposure to designer drugs/new psychoactive substances in our study population. This is a retrospective analysis of urine toxicology results from two different analytical platforms: a targeted, structurally confirmatory, high-performance liquid chromatography–tandem mass spectrometry (LC-MS/MS) assay that quantifies 136 drugs and metabolites including xylazine; and a non-targeted ThermoFisher Orbitrap Tribrid mass spectrometry system (Thermo ScientificTM, Bremen, Germany) in combination with database searches for the identification of drugs not captured by the targeted assay. All participants were patients receiving care through the Addiction Research and Treatment Services (ARTS), with documented substance misuse, undergoing routine urine drug toxicology testing at the iC42 Clinical Toxicology. Data analysis was performed using Sciex OS version 2.2.0.5738 after extraction using the targeted, structurally confirmatory and quantitative LC-MS/MS platform (SCIEX, Framingham, MA, USA). The drug patterns found in xylazine-positive and -negative urine samples were statistically significantly different (p < 0.001), indicating different consumption patterns associated with xylazine. Moreover, the overall concentrations of drugs (normalized to creatinine) were also statistically significantly different with higher concentrations in the urine samples that tested negative for xylazine. In contrast, samples that were positive for xylazine contained significantly higher concentrations of various designer drugs/new psychoactive substances as detected by the untargeted platform (p < 0.0001). The results indicated that xylazine has become increasingly common in Denver’s drug circulation and that xylazine may be used as a marker to prompt reflex testing with non-targeted high-resolution mass spectrometry assays in combination with database searches to test for the exposure to designer drugs/new psychoactive substances in our patient population.Keywords
This publication has 17 references indexed in Scilit:
- Enantiomeric Determination of Medetomidine in Street Drug Samples (August 2024—February 2025) and Implications for Immunoassay Test Strip AnalysisDrug Testing and Analysis, 2025
- Evaluating the Sensitivity, Selectivity, and Cross-Reactivity of Lateral Flow Immunoassay Xylazine Test StripsThe Journal of Applied Laboratory Medicine, 2025
- Xylazine in Overdose Deaths and Forensic Drug Reports in US States, 2019-2022JAMA Network Open, 2024
- Severe cutaneous ulcerations secondary to xylazine (tranq): A case seriesJAAD Case Reports, 2023
- Xylazine-induced acute skin necrosis in two patients who inject fentanylJAAD Case Reports, 2023
- Widespread Distribution of Xylazine Detected Throughout the United States in Healthcare Patient SamplesJournal of Addiction Medicine, 2023
- Xylazine spreads across the US: A growing component of the increasingly synthetic and polysubstance overdose crisisDrug and Alcohol Dependence, 2022
- A High-throughput HPLC-MS/MS Assay for the Detection, Quantification and Simultaneous Structural Confirmation of 136 Drugs and Metabolites in Human UrineTherapeutic Drug Monitoring, 2017
- The Emerging of Xylazine as a New Drug of Abuse and its Health Consequences among Drug Users in Puerto RicoJournal of Urban Health, 2012
- Severe Intoxication with the Veterinary Tranquilizer Xylazine in HumansJournal of Analytical Toxicology, 2001